martes, 17 de noviembre de 2026

Bispecific ADCs could unlock thousands of new cancer targets A logic-gated platform is expanding what's druggable in antibody-drug conjugate development by pairing antigens that cancer cells co-express but normal tissue does not. Written byAndrea Corona

Bispecific ADCs could unlock thousands of new cancer targets A logic-gated platform is expanding what's druggable in antibody-drug conjugate development by pairing antigens that cancer cells co-express but normal tissue does not. Written byAndrea Corona https://www.drugdiscoverynews.com/bispecific-adcs-could-unlock-thousands-of-new-cancer-targets-17476?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8BeCXrQ-kYqh0UDGsFW7MsK5S6FQvFNM2yshB0EKBOjmiPy3resXW8MMGgE5U4hZMtrWJ9y-Kdj3UkCYCJSzwHoXlf2A&_hsmi=449562183&utm_content=449562183&utm_source=hs_email Antibody-drug conjugates have transformed oncology over the past decade, but they have been working with a limited playbook. The same small set of validated ADCs — including HER2, TROP2, NECTIN4, cMET and a few others — has anchored most ADC programs, not because researchers lack ambition, but because the biology of what makes a safe ADC target is genuinely constrained. Promatix Biosciences, a UK-based biotech, is attempting to expand that constraint using a proteomics-driven cis-bispecific discovery platform. By identifying pairs of antigens that are co-expressed on cancer cells but rarely co-expressed in normal tissue, the company aims to move ADC development from a field limited by target scarcity to one enriched with first-in-class target combinations to evaluate.

No hay comentarios:

Publicar un comentario